Revenue
2019
2020
2021
2022
2023
2024
2025
PLIANT THERAPEUTICS, INC. (PLRX)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M | $41.8M | $57.1M |
| Research & development | $109.2M | $169.3M | $127.8M | $96.9M | $77.5M | $66.2M | $47.4M |
| Operating expenses | $156.4M | $228.4M | $185.7M | $136.9M | $105.1M | $83.5M | $58.3M |
| Operating income | −$156.4M | −$228.4M | −$184.1M | −$127.2M | −$97.5M | −$41.6M | −$1.2M |
| Net income | −$149.3M | −$210.3M | −$161.3M | −$123.3M | −$97.3M | −$41.5M | −$631,000 |
| Basic EPSper diluted share | -$2.43 | -$3.47 | -$2.75 | -$2.94 | -$2.71 | -$1.95 | -$4.22 |
| Diluted EPSper diluted share | -$2.43 | -$3.47 | -$2.75 | -$2.94 | -$2.71 | -$1.95 | -$4.22 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 20, 2026Form 4 · 10b5-1 | Cummings Keith LamontChief Financial Officer | SellCommon Stock | 24.0K | $1.28 | $30.7K | 297.2K |
| Jan 20, 2026Form 4 · 10b5-1 | Cheung LilyChief Human Resource Officer | SellCommon Stock | 7.5K | $1.28 | $9.6K | 44.8K |
| Jan 20, 2026Form 4 · 10b5-1 | Coulie BernardPresident and CEO | SellCommon Stock | 89.4K | $1.28 | $114.4K | 505.6K |
| Jan 20, 2026Form 4 · 10b5-1 | Kuo MinnieChief Operating Officer | SellCommon Stock | 6.9K | $1.28 | $8.9K | 37.8K |
| Jan 22, 2025Form 4 · 10b5-1 | Ouimette MikeGeneral Counsel & Corp. Sec'y | SellCommon Stock | 10.2K | $10.99 | $112.4K | 70.5K |